About
Narrative builds AI agents and AI-native end-to-end testing software for software engineering teams, replacing tools such as Playwright, Selenium, and Cypress. Its differentiation is self-healing testing that learns from a company’s code, product, and past regressions.
Market
Narrative competes in AI-native software quality assurance and automated browser/end-to-end testing, positioning itself as a replacement for legacy frameworks such as Playwright, Selenium, and Cypress. It differentiates through agents that learn a product's code, behavior, and past regressions to author, run, and self-heal tests, combined with no-code creation, AI assertions, parallel execution, and plain-English debugging reports.
Narrative targets software product companies—especially engineering teams shipping web applications—whose developers, QA practitioners, or engineering leads need faster, lower-maintenance end-to-end test coverage. The evidence does not establish a specific company-size band; named users include Nanonets, Commenda, Drumkit, Metal, and Vega.
At a Glance
Problem
Narrative addresses the cost and brittleness of conventional end-to-end software testing. Playwright, Selenium, and similar tools require teams to write and maintain scripted tests, while UI changes, timing issues, and flaky selectors create false failures and recurring engineering work. That pain is economically meaningful: flaky tests can consume an estimated 16–24% of developers’ time through reruns, investigations, and false alarms. The killer use case is continuously testing critical customer journeys on every pull request so regressions are caught before they reach users.
Product / Service
Narrative is an AI-native QA platform that learns a company’s code, product behavior, and past regressions, then authors, runs, and self-heals end-to-end tests. Teams can describe tests in product language or record user journeys, verify behavior through AI assertions, and run many browser sessions in parallel through CI/CD without maintaining selectors manually.
The platform also captures console logs, network activity, and video to accelerate debugging, produces plain-English bug reports, and suggests additional tests for uncovered critical paths. Its value proposition is broader test coverage with substantially less test-authoring and maintenance work, delivered through a hosted product with demos and a free trial.
Market
Narrative competes in AI-native software quality assurance and end-to-end test automation. Its named alternatives and incumbent technologies are Playwright, Selenium, and Cypress; the company’s differentiation is replacing code-heavy, scripted testing with AI agents, no-code test creation, self-healing, and natural-language failure analysis.
The company was founded in 2023, is an active Y Combinator Winter 2023 company, and publicly lists Nanonets, Commenda, Drumkit, Metal, and Vega as customers or users. Its site offers a demo and free trial, indicating an early commercial go-to-market motion. Public materials reviewed do not disclose revenue, so Narrative should not be labeled definitively pre-revenue; the best-supported characterization is an early-stage company with named customer traction and no verified public revenue figure.
Founders & Leadership
Funding History
Y Combinator
Recent News
A dated listing describes Narrative as an AI-powered end-to-end testing platform that helps engineering teams automate browser testing without relying on traditional testing frameworks.
Tracxn’s updated company profile identifies Narrative as a San Francisco seed company founded by Akshit Khurana and Suchit Dubey, developing an AI QA tool to automate software testing. The profile also links the company to trynarrative.com and describes features including no-code test creation, AI assertions, auto-healing, and CI/CD integration.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Narrative uses a demo-led B2B SaaS model: engineering teams book a demo and start a free trial, then convert to paid access. Exact subscription pricing is not disclosed in the available evidence.